Show simple item record

dc.contributor.authorZaragoza, Rafael
dc.contributor.authorEstella García, Ángel 
dc.contributor.authorNuvials, Xavier
dc.contributor.authorRobles Plaza, Mireya
dc.contributor.authorCasado Gómez, Araceli
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2026-11-05T11:11:47Z
dc.date.available2026-11-05T11:11:47Z
dc.date.issued2026-05-05
dc.identifier.issn2309-608X
dc.identifier.urihttp://hdl.handle.net/10498/40557
dc.description.abstractBackground: The objective was to identify management strategies of IFI in critically ill patients through a Spanish national survey. Methods: A cross-sectional multicentre survey among ICU specialists, experienced in IFI, was performed (22 April–25 July 2024). The survey consisted of 13 questions with four closed answers. Results: Sixty-three specialists from 51 hospitals of 16 regions completed the survey. 95% stated that, in high-risk patients with clinical suspicion of Pulmonary Aspergillosis (PA), galactomannan in BAL is performed to guide treatment. In the treatment of patients with PA and influenza, 86% declared that isavuconazole and liposomal amphotericin B are recommended treatments and in high suspicion of Aspergillus coinfection, 76% recommended empirical treatment waiting for microbiological confirmation. 90% declared that the use of Extracorporeal Membrane Oxygenation (ECMO) and Renal Replacement Therapies (RRT) could be associated with lower azole levels. Regarding intra-abdominal candidiasis, 78% that physiopathological changes in critically ill patients, reduce their entry into peritoneal fluid. Conclusions: The majority of the respondents agreed (>80%) on: In suspicion of PA, Galactomannan in BAL to guide treatment is mandatory; In case of aspergillosis and influenza, isavuconazole and liposomal amphotericin B are the recommended treatments; The use of ECMO and RRT could be associated with lower azole levels.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/es_ES
dc.sourceJournal of Fungi, Vol. 12, Núm. 5, 2026es_ES
dc.subjectinvasive fungal infectiones_ES
dc.subjectcritically ill patientses_ES
dc.subjectantifungal resistancees_ES
dc.subjectaspergillosises_ES
dc.subjectcandidiasises_ES
dc.titleIFUCISTRATEGY: A Spanish Survey on the Management of Invasive Fungal Infection (IFI) in Critically Ill Patientses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/JOF12050339
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional